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Abstract
Background: Nevirapine (NVP) single-dose is still a widely used antiretroviral prophylaxis for the prevention of vertical
HIV-1 transmission in resource-limited settings. However, the main disadvantage of the Non-nucleoside Reverse
Transcriptase Inhibitor (NNRTI) NVP is the rapid selection of NVP-resistant virus with negative implications for
subsequent NNRTI-based long-term antiretroviral therapy (ART). Here, we analysed the emergence of drug-resistant
HIV-1 including minor variants in the early phase after NVP single-dose prophylaxis and the persistence of drug-
resistant virus over time.
Methods and Findings: NVP-resistant HIV-1 harbouring the K103N and/or Y181C resistance mutations in the HIV-1 reverse
transcriptase gene was measured from 1 week up to 18 months after NVP single-dose prophylaxis in 29 Ugandan women
using allele-specific PCR assays capable of detecting drug-resistant variants representing less than 1% of the whole viral
population. In total, drug-resistant HIV-1 was identified in 18/29 (62%) women; rates increased from 18% to 38% and 44% at
week 1, 2, 6, respectively, and decreased to 18%, 25%, 13% and 4% at month 3, 6, 12 and 18, respectively. The proportion of
NVP-resistant virus of the total viral population was significantly higher in women infected with subtype D (median 40.5%)
as compared to subtype A (median 1.3%; p=0.032, Mann-Whitney U test). 33% of resistant virus was not detectable at week
2 but was for the first time measurable 6–12 weeks after NVP single-dose prophylaxis. Three (10%) women harboured
resistant virus in proportions .10% still at month 6.
Conclusions: Current WHO guidelines recommend an additional postnatal intake of AZT and 3TC for one week to avoid NVP
resistance formation. Our findings indicate that a 1-week medication might be too short to impede the emergence of NVP
resistance in a substantial proportion of women. Furthermore, subsequent NNRTI-based ART should not be started earlier
than 12 months after NVP single-dose prophylaxis.
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Introduction
Mother-to-child transmission of HIV-1 in developing countries
is still a major concern. Although more effective prophylaxis
regimens like the combination of 3 different antiviral drugs are
recommended by current WHO guidelines [1], nevirapine single-
dose (NVP-SD) is still a frequently used option in resource-
constrained settings due to its simplicity.
The major drawback, however, of using the Non-nucleoside
Reverse Transcriptase Inhibitor (NNRTI) NVP is the frequent
emergence of NVP-resistant HIV-1 variants even after single-dose
intake as a result of NVP’s low genetic barrier [2-7]. There is
evidence that treatment failure of a subsequent NVP- or other
NNRTI-based antiretroviral therapy (ART) is more likely for
women with prior NVP exposure which has been connected to
drug resistance [8-10]. Drug-associated resistance mutations in the
HIV-1 genome fade over time [2,3,5,11] but even drug-resistant
HIV-1 variants representing only a minor population of the total
viral population are important since they can also predispose to
treatment failure [12–14]. Limited data is available about the time
of emergence of minor drug-resistant HIV-1 in the early phase (1
to 2 weeks) after NVP-SD prophylaxis.
Here, we analysed the emergence and persistence of NVP-
resistant HIV-1 in Ugandan women mainly infected with subtype
A and D. Samples were taken at tight schedule from 1 week up to
18 months after NVP-SD intake. Highly sensitive allele-specific
PCR (ASPCR) assays were applied to quantify drug-resistant HIV-
1 at proportions as low as 1%.
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Ethics Statement
All study participants were HIV-1 positive pregnant women
enrolled in a prevention of mother-to-child (PMTCT) programme
at Fort Portal District Hospital (Kabarole District, western
Uganda) if they had given written informed consent. The study
was approved by the National ethical committee of Uganda
(National Council of Science and Technology) and by the ethical
committee of the Charite ´ - Universita ¨tsmedizin Berlin in
Germany.
All women had taken NVP-SD (200 mg) at the onset of labour
following the HIVNET012 protocol [15]. Blood samples were
taken at delivery (baseline), 1, 2 and 6 weeks and 3, 6, 12 and 18
months after NVP-SD intake. Women were included into the final
analysis if they had never taken antiretrovirals before NVP-SD
prophylaxis and if at least 4 samples after NVP-SD intake were
available. Additionally, the baseline sample from delivery
(supposed to contain HIV-1 wild type only) had to be amplifiable
in order to establish an individual cut-off in the ASPCR for
detection of NVP-resistant virus; quantification of drug-resistant
HIV-1 variants carrying the K103N and/or the Y181C mutation
in the pol gene were done by ASPCR assays as previously
described [16]. The detection limits for the 3 mutations as
estimated from plasmid DNA controls were 0.019% K103N
(AAC), 0.013% K103N (AAT) and 0.29% Y181C (TGT) in the
presence of wild-type HIV-1 [16].
Population-based sequencing which is a much less sensitive
method (detection limit for drug-resistant HIV-1 is approximately
20%) was conducted on all samples exhibiting NVP-resistant HIV-
1 and on 22% randomly chosen samples without evidence of drug-
resistant virus as determined by ASPCR. Population-based
sequencing was performed using the automated sequencer
3130xl Genetic Analyzer (Applied Biosystems, Darmstadt, Ger-
many) and the Viroseq HIV-1 Genotyping System version 2.0
(Abbott, Wiesbaden, Germany). For HIV-1 subtype analyses the
REGA HIV-1 subtyping tool was applied [17].
Statistical analysis was performed using the program SPSS,
version 17.0 (SPSS Inc, Chicago, IL, USA). The proportions of
K103N (codon AAC) and K103N (codon AAT) mutants were
summed to obtain the total proportion of virus harboring the
K103N mutation. Fisher’s exact test (two-tailed) was used to assess
significant associations among categorical variables like the
resistance frequencies between different HIV-1 subtypes. The
non-parametric Mann-Whitney U test was used to compare the
maximum proportions of NVP-resistant virus between women
infected with different subtypes. For this purpose, the maximum
proportion of K103N or Y181C ever observed during the
observation period of an individual was used as the presence of
both mutations on the same genome cannot be excluded; this
approach underestimates the total proportion of NVP-resistant
virus in case the 2 mutations are located on different HIV-1
genomes.
Results
29 women fulfilled the inclusion criteria and constituted the
final study group. The median baseline data were age 25 years
(IQR 22–29), parity 2 children (IQR 1.5–4.5), viral load 15050
copies/mL (IQR 6220–46725) and CD4 count 546 cells/mm3
(IQR 452–730). In total, 158 blood samples after NVP-SD intake
were available and amplifiable (mean: 5.5 samples per woman).
One mother started ART (d4T, 3TC and NVP) 6 months after
NVP-SD and thus during the observation period. 52% (n=15)
were infected with HIV-1 subtype A1, 38% (n=11) with subtype
D and 1 woman each with subtype C, subtype G and an HIV-1
isolate which was not assignable according to the REGA HIV-1
subtyping tool.
Altogether, 18/29 (62%) women developed NVP resistant virus
during the observation period (Table 1): 7/15 (47%) women with
subtype A1, 8/11 (73%) women with subtype D and the 3 women
infected with subtype C, subtype G and the unclassifiable isolate.
The frequency of resistance was not significantly different between
subtype A and subtype D (p=0.25, Fisher’s exact test).
9/18 (50%) women with resistance formation exhibited the
K103N and the Y181C mutation in their viral population. In 8 of
these women, both mutations were simultaneously present when
resistance formation was detected for the first time; in 1 woman
(Table 1, no. 10) the development of Y181C preceded the
emergence of K103N. In the remaining 9/18 women with
resistance formation the resistant virus carried either the K103N
(n=7) or the Y181C (n=2) mutation during the observation
period.
In 3 of the 18 women with resistant virus during the observation
period amplification of the week 2 samples failed. In 10 of the
remaining 15 women (67%), resistant variants were for the first
time detectable 1–2 weeks after NVP-SD. In 5/15 (33%) women
the resistance emerged later and was visible for the first time at
week 6 or in one woman (Table 1, no. 10 infected with subtype G)
at month 3, respectively.
Resistance formation took place in a time-dependent manner
with an increase in frequency up to week 6 followed by fading of
mutations. In detail, resistant virus was detectable in 2/11 (18%)
week 1 samples, in 9/24 (38%) week 2 samples, in 11/25 (44%)
week 6 samples, in 4/22 (18%) month 3 samples, in 7/28 (25%)
month 6 samples, in 3/24 (13%) month 12 samples and in 1/24
(4%) month 18 samples.
The maximum proportion of NVP-resistant HIV-1 of the total
viral population was higher in subtype D than in subtype A
samples (median 40.5% for subtype D versus 1.3% for subtype A,
Mann-Whitney U test: p=0.032).
In 50% (9/18) of the women having developed drug-resistant
HIV-1 variants, the relative proportion of the resistant population
did not exceed 5% during the whole study period. This applied to
5/7 (71%) women infected with HIV-1 subtype A1 and to 2/8
(25%) women infected with subtype D (p=0.13, Fisher’s exact
test).
At month 6, drug-resistant HIV-1 variants were still detectable
in 25% of the women; NVP-resistant virus at proportions higher
than 10% were detected in 3 women (10%). In 2 of these women
(Table 1, no. 24 and no. 27), the resistant HIV-1 population faded
away and was no longer detectable at month 12. In 1 woman
(Table 1, no. 19), the drug-resistant HIV-1 variant (100% Y181C)
which had emerged early at week 1 persisted throughout the whole
observation period and was still present at month 12 (18-month
sample was missing).
In another woman (Table 1, no. 9), the resistant virus
population being 10% (Y181C) at month 3 was not detectable
at month 6 and month 15 but re-emerged and constituted the
majority of the HIV-1 population at month 18; this woman was
infected with subtype C and had started NVP-containing ART 6
months after NVP-SD intake.
Population-based sequencing was conducted on all samples of
the 18 women exhibiting drug-resistant virus during the study
(n=37) and on 27 (22%) randomly chosen samples without
indication of drug-resistant virus by ASPCR. The results of
ASPCR and population-based sequencing matched very well; all
samples without detectable drug-resistant HIV-1 or with drug-
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were classified to contain HIV-1 wild type only by population
sequencing. In all samples harbouring NVP-resistant virus at
proportions higher than 20% in the ASPCR assays, population-
based sequencing confirmed the presence of drug-resistant virus.
Whenever population-based sequencing detected HIV-1 variants
carrying the K103N and/or Y181C mutation, the ASPCR assays
indicated the presence of these mutations as well.
Discussion
NVP-SD is widely used for prevention of mother-to-child
transmission of HIV-1 in resource-constrained settings but it
frequently induces resistance mutations in the HIV-1 genome [2–
7]. Here, we measured NVP-resistant HIV-1 at proportions as low
as 1% in 29 Ugandan women from 1 week up to 18 months after
NVP-SD prophylaxis. The aim of this study was to define the time
of emergence of NVP-resistant virus including minority variants
during the early phase after NVP-SD intake (1–2 weeks) and the
persistence of NVP-resistant HIV-1.
62% of the women developed resistant virus during the
observation period. The rate of resistant virus increased from
week 1 (18%) over week 2 (38%) to week 6 (44%) before it
continuously declined to 25% (month 6), 13% (month 12) and 4%
(month 18). Most likely, NVP concentrations at week 1 which were
shown to exceed the IC50 of NVP more than tenfold in most
Table 1. Nevirapine-resistant HIV-1 variants in plasma samples of 29 Ugandan women taken 1 week up to 18 months after
nevirapine (NVP) single-dose prophylaxis as analysed by allele-specific PCR (ASPCR).
proportion of NVP-resistant
HIV-1 in % by ASPCR
proportion of NVP-resistant
HIV-1 in % by ASPCR
no sub-type mutation w1 w2 w6 m3 m6 m12 m18 no sub-type mutation w1 w2 w6 m3 m6 m12 m18
1 A 1 K 1 0 3 N w t w tw tw tw tw tw t16 nt K103N n/a 2.2 1.7 wt 0.1 wt n/a
Y 1 8 1 C w t w tw tw tw tw tw t Y 1 8 1 C n / a 1.1 wt wt wt wt n/a
2 A1 K103N n/a wt wt n/a n/a n/a n/a 17 D K103N wt wt wt wt wt wt wt
Y181C n/a wt 0.5 n/a n/a n/a n/a Y181C wt wt wt wt wt wt wt
3 A1 K103N n/a 30 16 wt 0.5 wt n/a 18 A1 K103N n/a wt wt n/a wt wt wt
Y181C n/a 15 wt wt wt wt n/a Y181C n/a wt wt n/a wt wt wt
4 D K103N wt 9.4 7.0 wt wt wt wt 19 D K103N n/a 3.3 61 1.4 wt wt n/a
Y181C wt 45 0.6 wt wt wt wt Y181C n/a 100 100 100 100 100 n/a
5 A 1 K 1 0 3 N n / a n / a w tw tw tw tw t20 A1 K103N wt wt n/a wt wt wt wt
Y181C n/a n/a wt wt wt wt wt Y181C wt wt n/a wt wt wt wt
6 A1 K103N n/a wt n/a n/a wt n/a wt 21 A1 K103N wt wt wt wt wt wt wt
Y181C n/a wt n/a n/a wt n/a wt Y181C wt wt wt wt wt wt wt
7 D K103N wt wt 1.4 wt wt wt wt 22 A1 K103N n/a n/a wt wt wt n/a wt
Y 1 8 1 C w t w tw tw tw tw tw t Y 1 8 1 C n / a n / a 1.3 wt 0.9 n/a wt
8 D K103N 25 0.9 wt wt wt wt wt 23 A1 K103N n/a wt wt n/a wt wt wt
Y181C 11 8.4 wt wt wt wt wt Y181C n/a wt wt n/a wt wt wt
91 C K103N n/a 0.4 n/a wt wt * 0.05 wt 24 D K103N n/a wt 50 n/a 100 wt wt
Y181C n/a 16 n/a 9.8 wt * wt 55 Y181C n/a wt wt n/a wt wt wt
10 G K103N n/a wt wt wt 0.1 n/a wt 25 A1 K103N wt 3.3 wt n/a wt wt wt
Y181C n/a wt wt 0.5 wt n/a wt Y181C wt wt wt n/a wt wt wt
11 A1 K103N n/a 0.1 wt n/a wt 0.1 wt 26 A1 K103N 0.03 wt wt wt wt wt wt
Y181C n/a wt wt n/a wt wt wt Y181C wt wt wt wt wt wt wt
12 D K103N wt n/a 59 wt wt n/a wt 27 D K103N n/a 11 n/a 36 11 wt wt
Y181C wt n/a wt wt wt n/a wt Y181C n/a 30 n/a wt wt wt wt
13 D K103N n/a n/a wt wt wt wt n/a 28 D K103N n/a wt 0.1 wt wt wt wt
Y181C n/a n/a wt wt wt wt n/a Y181C n/a wt wt wt wt wt wt
14 A1 K103N wt n/a 21 wt wt wt wt 29 D K103N n/a wt wt wt wt wt wt
Y181C wt n/a 0.4 wt wt wt wt Y181C n/a wt wt wt wt wt wt
15 A1 K103N n/a wt wt wt wt wt wt
Y181C n/a wt wt wt wt wt wt
w: week; m: month
wt: wild-type HIV-1
n/a: not applicable (missing sample or sample that failed amplification)
1: start of antiretroviral long-term treatment at month 6 (d4T + 3TC + NVP)
*: sample collected at month 15
nt: not typable according to REGA-tool
doi:10.1371/journal.pone.0020357.t001
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resistant virus at this early time.
Higher rates of NVP-associated resistance mutations in HIV-1
subtype D strains as opposed to subtype A strains have been
observed in other studies [2]. In our study, the emergence of NVP-
resistance during the observation time (73% in subtype D versus
47% in subtype A) and the frequency of drug-resistant variants
exceeding 5% of the total viral population (75% in subtype D
versus 29% in subtype A) was more common in women infected
with subtype D than with subtype A; these differences were not
statistically significant, presumably due to the small sample size
(Fisher’s exact test: p=0.25 and p=0.13, respectively). However,
the maximum proportions of the NVP-resistant HIV-1 population
in subtype D samples (median 40.5%) significantly exceeded those
in subtype A (median 1.3%) samples (p=0.032, Mann-Whitney U
test).
50% of the women with resistance formation never harboured
NVP-resistant variants at proportions higher than 5%. However,
even these minor variants are of great importance as they were
shown to increase the risk of subsequent treatment failure using
NNRTI-containing ART [12–14].
An interval of 6 months between NVP prophylaxis and
NNRTI-based ART seemed to be sufficient for unrestricted
treatment response in a trial conducted in Botswana [10].
However, in our study, NNRTI-resistant virus was present in
25% of the women at month 6. Furthermore, 3 women (10%, all
subtype D) exhibited proportions of resistant HIV-1 higher than
10% (K103N: 11%, K103N: 100%, Y181C: 100%) at month 6.
Starting ART in these women 6 months after NVP-SD would
probably lead to the outgrowth of resistant virus, thus preparing
the ground for treatment failure. Therefore, the proposed 6-month
interval between NVP prophylaxis and start of NNRTIs including
ART may not be long enough for all women. Consistently,
Stringer et al. [8] recommended recently not to start an NNRTI-
containing drug regimen within the first 12 months after NVP-SD
intake as they found an increased risk of treatment failure in
Zambian, Kenyan and Thai women up to 1 year after NVP-SD.
It poses a fundamental problem that the same drug is used as
single-dose for prophylaxis and as part of subsequent ART.
Unfortunately, neither extended combination prophylaxis regi-
mens nor NNRTI-sparing ART using a protease inhibitor are
currently realistic options in many resource-limited settings.
Of note, in the only woman who started ART during the
observation period (Table 1, no. 9, start of NVP-containing
treatment at month 6), resistant virus harbouring the Y181C
mutation re-emerged under ART. In this woman infected with
HIV-1-subtype C, drug-resistant virus was detectable early after
NVP-SD intake (Y181C: 16% at week 2), disappeared and was still
undetectable 9 months after the initiation of ART. However, 12
months after starting ART the majority of the viral population
carried the Y181C mutation. Most likely, the resistant virus was
selected, archived under NVP-SD and reappeared under the
selection pressure of NVP-containing ART. Recently, it was
shown that NVP-resistant HIV-1 arising after NVP-SD intake can
indeed be archived as stably integrated provirus within the latent
reservoir of resting CD4 cells [19].
Resistant viruses emerged in most women about 2 weeks after
intake of NVP-SD. In one third of the women, however, drug-
resistant virus was not detectable 2 weeks after NVP-SD intake but
emerged later. Current WHO PMTCT guidelines recommend the
additional postnatal intake of AZT and 3TC to reduce NVP
resistance formation [1]. According to our results a 1-week course
will not be sufficient to avoid the development of NVP-resistant
virus in a considerable proportion of women. Accordingly, other
studies have shown that 7–10% of women still exhibited NVP-
resistant virus 6 weeks after NVP-SD intake despite a postnatal 1-
week course of AZT and 3TC [20,21]. This indicates that a 7-day
postpartum course of AZT/3TC can diminish but not eliminate
the selection of NVP resistance mutations. It is therefore
conceivable that an extension of the postnatal drug intake could
further diminish the emergence of NVP resistant virus. In fact,
Lallemant et al. applied a 1-month postpartum course of AZT plus
didanosine and almost completely prevented the selection of NVP-
resistant HIV-1 (0% resistant virus using population sequencing
and 1.8% resistant virus using a highly sensitive assay) [22]. In this
context it is important to note that none of the dual short-course
antiretroviral prophylaxis regimens fully suppresses viral replica-
tion and all share the disadvantage of not preventing postnatal
transmission via breastfeeding. Recently, the Kesho Bora study
and other trials have proven that maternal highly active ART
during pregnancy and breastfeeding efficiently reduces vertical
transmission as well as the emergence of drug-resistant virus [23–
26] thus maximizing future treatment options. These findings are
reflected in the latest WHO PMTCT guidelines which recom-
mend as one option highly active ART for all HIV positive
pregnant women irrespective of their CD4 cell count [1]. On the
other hand, possible negative implications of highly active ART
like higher rates of preterm delivery, lower birth weight and
cardiac effects in infants have to be considered and counterbal-
anced [27–29]. It is crucial to define the best option for prevention
of mother-to-child transmission in order to reduce the burden of
HIV/AIDS in these most severely affected regions.
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